Report cover image

Leishmaniasis - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 40 Pages
SKU # DEL18679715

Description

Leishmaniasis - Pipeline Insight, 2024



DelveInsight’s, “Leishmaniasis - Pipeline Insight, 2024,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Leishmaniasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Leishmaniasis Understanding

Leishmaniasis: Overview

Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a neglected tropical disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

""Leishmaniasis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Leishmaniasis pipeline landscape is provided which includes the disease overview and Leishmaniasis treatment guidelines. The assessment part of the report embraces, in depth Leishmaniasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Leishmaniasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Leishmaniasis R&D. The therapies under development are focused on novel approaches to treat/improve Leishmaniasis.
Leishmaniasis Emerging Drugs Chapters

This segment of the Leishmaniasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Leishmaniasis Emerging Drugs
  • LXE408: Novartis
DNDi and Novartis initiated a collaboration and licence agreement in early 2020 to jointly develop LXE408 – a first-in-class compound, discovered at Novartis with financial support from Wellcome – as a potential new oral treatment for visceral leishmaniasis. Currently, it is in Phase II stage of development.
  • GSK 3494245: GlaxoSmithKline
GSK 3494245 is a Proteasome inhibitor being developed by GlaxoSmithKline for the treatment of patients with Leishmaniasis. The drug is currently in phase 1 stage of development.

Further product details are provided in the report……..

Leishmaniasis: Therapeutic Assessment

This segment of the report provides insights about the different Leishmaniasis drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Leishmaniasis
There are approx. 4+ key companies which are developing the therapies for Leishmaniasis. The companies which have their Leishmaniasis drug candidates in the most advanced stage, i.e. phase II include, Novartis.
  • Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Leishmaniasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Leishmaniasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leishmaniasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leishmaniasis drugs.

Leishmaniasis Report Insights
  • Leishmaniasis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Leishmaniasis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Leishmaniasis drugs?
  • How many Leishmaniasis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Leishmaniasis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Leishmaniasis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Leishmaniasis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Novartis
  • GlaxoSmithKline
  • MedC Biopharma Corporation
  • Drugs for Neglected Diseases Initiative Foundation
  • Infan Industria Quimica Farmaceutica Nacional
Key Products
  • LXE408
  • GSK 3494245
  • GSK 3186899
  • DNDI 6148
  • DMD 2010
  • DNDI 6174
  • 18-Methoxycoronaridine

Table of Contents

40 Pages
Introduction
Executive Summary
Leishmaniasis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Leishmaniasis – DelveInsight’s Analytical Perspective
Mid Stage Products (Phase II)
Comparative Analysis
LXE408: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
GSK 3494245: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Leishmaniasis Key Companies
Leishmaniasis Key Products
Leishmaniasis- Unmet Needs
Leishmaniasis- Market Drivers and Barriers
Leishmaniasis- Future Perspectives and Conclusion
Leishmaniasis Analyst Views
Leishmaniasis Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us